Guangzhou Innogen Pharmaceutical Group Co., Ltd (HKG:2591)

Hong Kong · Delayed Price · Currency is HKD

3.850

+0.010 (0.26%)

Sep 18, 2026, 4:08 PM HKT

Market Cap	1.76B -91.5%
Revenue (ttm)	176.96M +171.6%
Net Income	-386.00M
EPS	-0.85
Shares Out	456.82M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,301,690
Open	3.870
Previous Close	3.840
Day's Range	3.840 - 3.950
52-Week Range	3.435 - 48.360
Beta	n/a
Analysts	Strong Buy
Price Target	20.58 (+434.55%)
Earnings Date	Nov 25, 2026

About HKG:2591

Guangzhou Innogen Pharmaceutical Group Co., Ltd engages in the development of drug engaged in the research, development and commercialization of pharmaceutical products. The company’s products are used for the treatment of metabolic diseases, including diabetes, obesity and overweight, and MASH; and other major central nervous system diseases. The company was incorporated in 2014 and is based in Shanghai, China. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2014

Employees 103

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2591

Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 2591 stock is "Strong Buy." The 12-month stock price target is $20.58, which is an increase of 434.55% from the latest price.

Price Target

$20.58

(434.55% upside)

Analyst Consensus: Strong Buy

Stock Forecasts